权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

URCC NCORP Research Base

URCC NCORP研究基地

基本信息

批准号：
10460279
负责人：
KAREN M. MUSTIAN
金额：
$ 587.72万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10460279
关键词：
Achievement Age American Society of Clinical Oncology Award Behavioral Biological Biological Markers Cancer Center Cancer Control Cancer Control Research Cancer Patient Cancer Survivor Caregivers Caring Clinic Clinical Clinical Cancer Center Clinical Oncology Clinical Research Clinical Research Associate Clinical Trials Cluster randomized trial Collection Committee Members Communities Community Clinical Oncology Program Community Networks Conduct Clinical Trials Data Development Enrollment Epigenetic Process Ethics Ethnic Origin Etiology Funding Gender Goals Grant Immunologics Immunotherapy Individual Innovative Therapy Institutes Intervention Journals Knowledge Leadership Malignant Neoplasms Manuscripts Medical Oncologist Mentors Minority Minority Groups Modernization Morbidity - disease rate NCI Center for Cancer Research National Cancer Institute Nature Nurses Oncologist Oncology Operative Surgical Procedures Outcome Pathway interactions Patient Care Patients Peer Review Persons Phase Physicians Physiological Pilot Projects Positioning Attribute Prevalence Procedures Productivity Program Development Prospective cohort study Protocols documentation Publications Publishing Quality of Care Race Radiation Oncologist Radiation therapy Randomized Randomized Clinical Trials Reduce health disparities Reporting Research Research Personnel Resources Risk Scientific Inquiry Severities Sex Orientation Site Supportive care Surgeon Survivors Symptoms System Testing Time Toxic effect Training Treatment Side Effects Treatment-related toxicity Underserved Population United States Universities Vision Woman Work anticancer research base cancer care cancer therapy care delivery chemotherapy clinical care data acquisition design experience gene therapy health disparity health equity hormone therapy human subject protection improved innovation intervention delivery investigator training member novel participant enrollment programs psychosocial recruit side effect stem symptom science system-level barriers treatment guidelines virtual

项目摘要

ABSTRACT: The University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base (RB) is a RB with 35+ years of experience conducting cancer control research (CCR) and cancer care delivery research (CCDR). The URCC NCORP RB’s vision is "to help good people through lousy times when they experience cancer” by reducing cancer- and treatment- related morbidity stemming from toxicities and side effects. Since 2014, 35% (N=2,831) of all NCORP accrual credits resulted from enrollment of patients and survivors by our Community Affiliates on our 13 active URCC clinical trials. URCC and its Community Affiliates also enrolled 421 caregivers and more than 300 oncologists to our 13 active trials, as well as 1,752 patients and survivors to our 29 local pilot studies. URCC successfully enrolled and randomized over 30 individual community oncology practices to cluster randomized trials. Our investigators and staff submitted 8 new concepts/grants, with 18 new concepts/grants currently in development, and 29 active pilot studies. The significant and innovative contribution of URCC research to scientific knowledge and clinical care is evidenced by 1) 197 published manuscripts, 2) 209 presented abstracts, 3) 25 podium presentations at ASCO, 4) 82 outstanding research awards to our investigators, 5) 12 junior investigators successfully trained to conduct research in NCORP, and 6) 2,215 investigators, clinicians, and staff successfully trained to implement URCC NCORP RB protocols at community sites across the United States. Notable recognition of the significance of research conducted by the URCC RB and its investigators includes: 1) Best of JCO publication for 2017, 2) most cited article in JAMA Oncology for 2017, 3) one of the most significant advances in cancer research and care for 2018, 4) citation of our published research in virtually all existing supportive care treatment guidelines, and 5) leadership by 5 of our RB Executive Committee members in the development of 4 supportive care treatment guidelines. We accomplish our goal of reducing cancer- and treatment-related morbidity by working with cancer patients, survivors, and their caregivers from 592 community oncology practices across the United States to design and conduct CCR and CCDR, including translational and health equity outcomes, focused in symptom science. Our research develops and tests novel treatments for toxicities and side effects stemming from cancer and its treatments. We design and conduct phase I-III randomized clinical trials and longitudinal, prospective cohort studies. To meet its responsibilities as a RB and maintain its high level of productivity over the next funding period, the URCC RB will focus its resources and expertise on the following specific aims: Aim 1) to conduct CCR, Aim 2) to conduct CCDR, Aim 3) to conduct translational CCR, Aim 4) to conduct health equity CCR and CCDR, and Aim 5) to provide state-of-the-art training and mentoring for NCORP investigators and staff. With its proven track record of productivity and innovation, the URCC NCORP RB is expertly positioned to continue its pioneering symptom science research in the NCORP Network.

摘要：罗彻斯特大学癌症中心（URCC）国家癌症研究所社区